The In Vitro Lipolysis of Lipid-Based Drug Delivery Systems: A Newly Identified Relationship between Drug Release and Liquid Crystalline Phase

Table 3

Equilibrium solubilities at 37°C of indomethacin in digestion buffer pH 7.5, in NaTDC/PC and in blank aqueous phases obtained from drug-free lipid formulations digest (simulated fed state) (, ).

Medium	Equilibrium solubilities 37°C (μg·mL^−1)
Digestion buffer	299.73 ± 22.15
NaTDC/PC	2009.55 ± 45.92
Type I + NaTDC/PC	2192.26 ± 12.33
Type II + NaTDC/PC	2336.14 ± 97.67
Type IIIA + NaTDC/PC	2547.14 ± 54.65
Type IIIB + NaTDC/PC	2758.14 ± 61.37
Type IV + NaTDC/PC	2901.14 ± 35.86
Aqueous phase from lipid formulation digested Type I	4702.30 ± 323.21
Aqueous phase from lipid formulation digested Type II	4355.77 ± 28.62
Aqueous phase from lipid formulation digested Type IIIA	3587.67 ± 78.50
Aqueous phase from lipid formulation digested Type IIIB	3240.28 ± 243.94
Aqueous phase from lipid formulation digested Type IV	2951.54 ± 22.54

versus NaTDC/PC, Type I + NaTDC/PC, Type II + NaTDC/PC, Type IIIA + NaTDC/PC, and Type IIIB + NaTDC/PC.